Cardiff Oncology Appoints New CMO, Directors
Ticker: CRDF · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, officer-appointment
TL;DR
Cardiff Oncology brings in new CMO and board members, potentially signaling a new phase for their clinical programs.
AI Summary
Cardiff Oncology, Inc. announced on June 13, 2025, the appointment of Dr. Michael H. Kalos as Chief Medical Officer and the election of Dr. Steven M. Altschuler and Mr. David M. E. Smith to its Board of Directors. The company also reported on compensatory arrangements for its officers. This filing follows previous name changes from Trovagene, Inc. and Xenomics Inc.
Why It Matters
The appointment of a new Chief Medical Officer and board members can signal strategic shifts or new directions for the company's drug development and clinical trials.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 20250613 — Report Date (Date of earliest event reported)
- 001-35558 — SEC File Number (Cardiff Oncology's SEC file number)
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Registrant
- Dr. Michael H. Kalos (person) — Appointed Chief Medical Officer
- Dr. Steven M. Altschuler (person) — Elected to Board of Directors
- Mr. David M. E. Smith (person) — Elected to Board of Directors
- Trovagene, Inc. (company) — Former Company Name
- Xenomics Inc (company) — Former Company Name
FAQ
Who has been appointed as the new Chief Medical Officer for Cardiff Oncology?
Dr. Michael H. Kalos has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors of Cardiff Oncology?
Dr. Steven M. Altschuler and Mr. David M. E. Smith were elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated June 13, 2025.
What were Cardiff Oncology's previous company names?
Cardiff Oncology, Inc. was formerly known as Trovagene, Inc. and Xenomics Inc.
What items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, other events, and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 by Dr. Michael H. Kalos regarding Cardiff Oncology, Inc. (CRDF).